Linking biochemical and cellular efficacy of MERS coronavirus main protease inhibitors.

Authors

Van N T La, Noa Lahav, Moshe Goldsmith, Mario Rodriguez, Randy Diaz-Tapia, Rebecca Pearl, Briana McGovern, Jared Benjamin, Haim Barr, Kris M White, Lulu Kang, John D Chodera, David D L Minh

Published in

ACS pharmacology & translational science. Jun 24, 2026. Epub Jun 24, 2026.

Abstract

Compounds that bind to the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) main protease (MPro) often produce biphasic concentration-response curves (CRCs) in biochemical assays; low concentrations activate the enzyme and high concentrations inhibit it. This biphasic behavior complicates data analysis. Here, we compare three approaches to data analysis: fitting the Hill equation to full inhibition phase, fitting it to the inhibition phase based on the negative control, and fitting an enzyme kinetics model that incorporates dimerization and ligand binding to the complete CRC. In the latter case, cellular efficacy is predicted by extrapolating the model to high enzyme concentrations. For compounds in our drug lead series, all three procedures yield inhibitory concentrations that are correlated with live-virus antiviral assays. The latter procedure provides the most accurate forecast of cellular efficacy rank. These data analysis procedures may be valuable for antiviral drug discovery against MERS-CoV MPro and other enzymes with similar kinetics.

PMID:
42422564
Bibliographic data and abstract were imported from PubMed on 09 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.